Burden of lymphoma in China, 1990−2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019

Liu, Weiping; Liu, Jiangmei; Song, Yuqin; Wang, Xiaopei; Mi, Lan; Cai, Cai; Zhao, Di; Wang, Lijun; Ma, Jun; Zhu, Jun

doi:10.18632/aging.204006

Cited by 22 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral T/NK-cell lymphoma (PTCL) is a group of rare and highly heterogeneous malignant lymphoproliferative diseases originating from mature T- and NK-cells. PTCL is classified into subtypes such as angioimmunoblastic T-cell lymphoma (AITL), ALK-positive anaplastic large-cell lymphoma (ALK+ALCL), ALK-negative anaplastic large-cell lymphoma (ALK-ALCL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), and so on ( 1 , 2 ). Most subtypes have a dismal prognosis ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

Gao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundThe role of consolidation therapy with autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL) in first complete remission (CR1) or partial remission (PR1) remains controversial. The existing data from China are limited. Therefore, we aimed to investigate the effect of ASCT on the survival of Chinese patients with PTCL showing response to induction chemotherapy at our hospital.MethodsWe retrospectively reviewed the data of patients with PTCL (excluding Natural killer/T cell lymphoma) in CR1 or PR1 treated at Peking University Hospital &Institute from 1996 to 2020. Propensity score matching (PSM) was used to balance clinical characteristics between the ASCT and non-ASCT groups. The primary endpoints were event-free survival (EFS) and overall survival (OS).ResultsOf the 414 selected patients, 73 received ASCT consolidation and 341 did not. Over a median follow-up of 5.7 years, survival was significantly better in the ASCT group than in the non-ASCT group (median EFS, 8.1 years vs. 2.8 years, P = 0.002; median OS, 14.9 years vs. 10.2 years, P = 0.007). The 5-year EFS and OS rates were 68.4% and 77.0% in ASCT group, and 43.2% and 57.6% in non-ASCT group, respectively. The survival benefit was confirmed in the propensity score matched cohort (46 patients who received ASCT and 84 patients who did not receive ASCT): P = 0.007 for median EFS and P = 0.022 for the median OS. Cox regression analysis showed that ASCT was independently associated with better survival: hazard ratio (HR) for EFS, 0.46 (95% CI: 0.28-0.76); HR for OS, 0.50 (95% CI: 0.31-0.84). Subgroup analysis showed that ASCT was more likely to benefit higher-risk patients and those with advanced disease. Among the subtypes of PTCL, the benefit was significant in angioimmunoblastic T-cell lymphoma (HR = 0.26 [95% CI: 0.10-0.66] for EFS and 0.29 [95% CI: 0.12-0.74] for OS), but not in the other subtypes.ConclusionASCT may improve the long-term survival of patients with PTCL in first CR or PR, especially for patients with angioimmunoblastic T-cell lymphoma. The specific groups most likely to benefit from upfront ASCT need to be clearly identified.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

Gao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[2] A sub-analysis demonstrated that there were an estimated 9,468 new cases and 2,709 deaths due to HL, 91,954 new cases and 44,310 deaths due to NHL, and 18,790 new cases and 13,420 deaths due to MM in China in 2019. [3,4] The disease burden of lymphoma and MM will continue to be exacerbated because of population growth, aging and increasing prevalence of risk factors. [5] Autologous hematopoietic stem cell transplantation (AHSCT) is an important therapeutic strategy to improve the survival outcome of lymphoma and MM, and the number of cases treated with this therapy has been increasing in the past two decades.…”

Section: Introductionmentioning

confidence: 99%

Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China

Liu

Jie

Zou

et al. 2022

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Little is known regarding the utilization rate of autologous hematopoietic stem cell transplantation (AHSCT) for lymphoma and multiple myeloma (MM) in the mainland of China. In 2019, the autologous stem cell transplantation group of Chinese Society of Clinical Oncology reported 4556 rst transplantations with a utilization rate of 3.8% for lymphoma and MM. The AHSCT utilization rates were 2.4% for lymphoma and 11.3% for MM. For lymphoma, the transplantation utilization rate was over 5.0% in the age group of 20-50 years with a peak of 6.5% in the age group of 40-44 years; for MM, the rate was over 10.0% in the age group of 35-65 with a peak of 33.8% in the age group of 45-49 years. The eastern region had higher transplantation utilization rate than central and western regions (4.6% vs. 3.0% vs. 3.3%). There was a wide gap in AHSCT utilization rates between the developed and developing provinces. Beijing had the highest transplantation utilization rate for both lymphoma and MM. This study provided a comprehensive evaluation of AHSCT utilization for lymphoma and MM in China, which will be useful for policy-making with respect to healthcare resource allocation and disease control strategies.

show abstract

“…This retrospective study comprised a review of the clinical data of patients diagnosed between 1 st January 2007 and 30 st June 2021 at Peking University Cancer Hospital. The key inclusion criteria included ( 1 ) HBsAg-positive ( 2 ); confirmed diagnosis of DLBCL using a biopsy specimen ( 3 ); receipt of at least four cycles of R-CHOP immunochemotherapy; and ( 4 ) treated with prophylactic antivirals. The exclusion criteria comprised ( 1 ) involvement of the central nervous system; and ( 2 ) Human immunodeficiency virus or Hepatitis C virus coinfection.…”

Section: Methodsmentioning

confidence: 99%

“…The key inclusion criteria included ( 1 ) HBsAg-positive ( 2 ); confirmed diagnosis of DLBCL using a biopsy specimen ( 3 ); receipt of at least four cycles of R-CHOP immunochemotherapy; and ( 4 ) treated with prophylactic antivirals. The exclusion criteria comprised ( 1 ) involvement of the central nervous system; and ( 2 ) Human immunodeficiency virus or Hepatitis C virus coinfection. To evaluate the effect of infection with HBV on the prognosis of DLBCL, we chose a control group who were not infected with HBV (negative for both HBsAg and HBcAb).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era

Nuersulitan

Li²,

Mi³

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Patients with lymphoma who are also infected with Hepatitis B virus (HBV) have a poor prognosis. This could be partly explained by the delay or premature termination of anti-tumor treatment because of HBV reactivation. However, there is limited data on the survival outcome of patients HBV-related lymphoma in the era of prophylactic antivirals. Data for 128 patients with HBV surface antigen-positive diffuse large B-cell lymphoma was collected. The median age was 54 years and the ratio of men to women was 1.2:1. All patients received immune-chemotherapy and prophylactic antiviral therapy. The median number of cycles of immune-chemotherapy was six. The overall response rate was 82%, with a complete remission rate of 75%. With a median follow-up of 58.4 months, the 5-year progression-free survival and overall survival rates were 75.7% and 74.7%, respectively. Nine patients experienced HBV reactivation but none experienced HBV-associated hepatitis. Patients with low and high HBV DNA loads had comparable survival outcomes. In conclusion, HBV infection had no negative effect on the prognosis of DLBCL in the era of prophylactic antiviral therapy.

show abstract

Burden of lymphoma in China, 1990−2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019

Cited by 22 publications

References 26 publications

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis

Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era

Contact Info

Product

Resources

About